When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Breakeven?

Simply Wall St · 08/31 14:36

With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) future prospects. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. With the latest financial year loss of US$140m and a trailing-twelve-month loss of US$84m, the US$7.6b market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Intra-Cellular Therapies will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for Intra-Cellular Therapies

According to the 15 industry analysts covering Intra-Cellular Therapies, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of US$72m in 2025. Therefore, the company is expected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 65% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

earnings-per-share-growth
NasdaqGS:ITCI Earnings Per Share Growth August 31st 2024

Given this is a high-level overview, we won’t go into details of Intra-Cellular Therapies' upcoming projects, however, bear in mind that typically pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one aspect worth mentioning. Intra-Cellular Therapies currently has no debt on its balance sheet, which is rare for a loss-making pharma, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of Intra-Cellular Therapies to cover in one brief article, but the key fundamentals for the company can all be found in one place – Intra-Cellular Therapies' company page on Simply Wall St. We've also compiled a list of important aspects you should look at:

  1. Valuation: What is Intra-Cellular Therapies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Intra-Cellular Therapies is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Intra-Cellular Therapies’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.